ArticleOncogene2020

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.

Sean P Kennedy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.